Zoladex in advanced breast cancer

Area of Science:

• Oncology
• Endocrinology

Background:

• Advanced breast cancer treatment in premenopausal women often involves ovarian suppression.
• Surgical oophorectomy and LHRH analogues are established methods for achieving this suppression.

Purpose of the Study:

• To compare the efficacy of Zoladex (goserelin), an LHRH analogue, with surgical oophorectomy in premenopausal patients with advanced breast cancer.
• To evaluate the endocrine effects of Zoladex alone and in combination with tamoxifen (Nolvadex) on serum hormone levels.

Main Methods:

• A study involving 53 premenopausal patients treated with Zoladex for advanced breast cancer.
• A subgroup of 34 premenopausal patients received Zoladex in combination with tamoxifen.
• Serum oestradiol and progesterone levels were monitored to assess endocrine response.

Main Results:

• Zoladex demonstrated a response rate similar to surgical oophorectomy.
• Zoladex induced castrate levels of serum oestradiol and progesterone in most patients, with some experiencing intermittent oestradiol peaks.
• The combination of Zoladex and tamoxifen resulted in significantly lower serum oestradiol levels, achieving castrate levels in all patients.

Conclusions:

• Zoladex is an effective alternative to surgical oophorectomy for ovarian suppression in premenopausal women with advanced breast cancer.
• Combination therapy with Zoladex and tamoxifen achieves profound oestradiol suppression.
• Further prospective randomized studies are warranted to determine the clinical benefit of combining Zoladex with tamoxifen.